ICI Pharma's Nolvadex (tamoxifen)
ICI Pharma's Nolvadex (tamoxifen): Anti-estrogen drug receives supplemental approval for use in treating breast cancer in premenopausal women, as alternative to mastectomy. The oral hormone product is already indicated as a treatment for postmenopausal breast cancer and for use either alone or in combination with other anticancer agents following surgery in postmenopausal node-positive patients. The company estimates the U.S. patient population for the new indication at 14,000: 5,000 women who have advanced disease at diagnosis and 9,000 women with recurring disease.
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.